Neurology
Found 6 results
Filters: Keyword is Outcome Assessment, Health Care  [Clear All Filters]
2019
Merkies ISJ, van Schaik IN, Léger J-M, Bril V, van Geloven N, Hartung H-P, Lewis RA, Sobue G, Lawo J-P, Durn BL et al..  2019.  Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies.. J Peripher Nerv Syst. 24(1):48-55.
Perumal J, Fox RJ, Balabanov R, Balcer LJ, Galetta S, Makh S, Santra S, Hotermans C, Lee L.  2019.  Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE.. BMC Neurol. 19(1):116.
Mielke O, Bril V, Cornblath DR, Lawo J-P, van Geloven N, Hartung H-P, Lewis RA, Merkies ISJ, Sobue G, Durn B et al..  2019.  Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre-randomization phase of the Polyneuropathy And Treatment with Hizentra study.. J Peripher Nerv Syst. 24(1):72-79.
2017
Robbins MS, Haut SR, Lipton RB, Milstein MJ, Ocava LC, Ballaban-Gil K, Moshé SL, Mehler MF.  2017.  A dedicated scholarly research program in an adult and pediatric neurology residency program.. Neurology. 88(14):1366-1370.
Kappos L, Havrdova E, Giovannoni G, Khatri BO, Gauthier SA, Greenberg SJ, You X, Wang P, Giannattasio G.  2017.  No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study.. Mult Scler. 23(13):1736-1747.
2016
Murthy SB, Urday S, Beslow LA, Dawson J, Lees K, W Kimberly T, Iadecola C, Kamel H, Hanley DF, Sheth KN et al..  2016.  Rate of perihaematomal oedema expansion is associated with poor clinical outcomes in intracerebral haemorrhage.. J Neurol Neurosurg Psychiatry. 87(11):1169-1173.